Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products. It primarily focuses on liquid products, including injectable, oral liquid, and ophthalmic products. The company develops EM-100, an ophthalmic product for the treatment of allergic conjunctivitis; ET-202 and ET-203, which are injectable product candidates for use in the hospital setting; ET-103, an oral liquid product candidate for hypothyroidism; ET-101, ET-102, and ET-104, which are oral liquid product candidates for neurological indications; and CT-100, a synthetic corticotropin therapeutic candidate for rheumatoid arthritis. It also develops DS-300, an injectable nutrition product candidate for neonates; DS-200, an injectable nutrition product for use as a supplement to intravenous solutions; and DS-100, an injectable nerve block for the relief of intractable pain. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone847-787-7361
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees15
Next Earnings Date3/23/2020 (Estimated)
OptionableNot Optionable
Eton Pharmaceuticals (NASDAQ:ETON) Frequently Asked Questions
What is Eton Pharmaceuticals' stock symbol?
Eton Pharmaceuticals trades on the NASDAQ under the ticker symbol "ETON."
How were Eton Pharmaceuticals' earnings last quarter?
Eton Pharmaceuticals Inc (NASDAQ:ETON) posted its quarterly earnings results on Thursday, November, 14th. The company reported ($0.28) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.23) by $0.05. View Eton Pharmaceuticals' Earnings History.
When is Eton Pharmaceuticals' next earnings date?
What price target have analysts set for ETON?
3 brokerages have issued twelve-month target prices for Eton Pharmaceuticals' stock. Their forecasts range from $13.50 to $23.00. On average, they expect Eton Pharmaceuticals' share price to reach $18.25 in the next year. This suggests a possible upside of 238.0% from the stock's current price. View Analyst Price Targets for Eton Pharmaceuticals.
What is the consensus analysts' recommendation for Eton Pharmaceuticals?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eton Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eton Pharmaceuticals.
Has Eton Pharmaceuticals been receiving favorable news coverage?
News stories about ETON stock have been trending positive on Friday, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Eton Pharmaceuticals earned a news impact score of 3.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for Eton Pharmaceuticals.
Are investors shorting Eton Pharmaceuticals?
Eton Pharmaceuticals saw a decrease in short interest during the month of January. As of January 31st, there was short interest totalling 313,200 shares, a decrease of 24.1% from the January 15th total of 412,700 shares. Based on an average daily trading volume, of 72,800 shares, the days-to-cover ratio is currently 4.3 days. Approximately 2.8% of the shares of the company are sold short. View Eton Pharmaceuticals' Current Options Chain.
Who are some of Eton Pharmaceuticals' key competitors?
Some companies that are related to Eton Pharmaceuticals include Merus (MRUS), Avedro (AVDR), AnaptysBio (ANAB), Puma Biotechnology (PBYI), OrganiGram (OGI), Avadel Pharmaceuticals (AVDL), Galera Therapeutics (GRTX), Kindred Biosciences (KIN), Fulcrum Therapeutics (FULC), Xenon Pharmaceuticals (XENE), INDIVIOR PLC/S (INVVY), Dynavax Technologies (DVAX), Calithera Biosciences (CALA), Organogenesis (ORGO) and Rigel Pharmaceuticals (RIGL).
What other stocks do shareholders of Eton Pharmaceuticals own?
Who are Eton Pharmaceuticals' key executives?
Eton Pharmaceuticals' management team includes the folowing people:
- Mr. Sean E. Brynjelsen, Pres, CEO & Director (Age 47)
- Mr. W. Wilson Troutman CPA, CFO, Treasurer & Sec. (Age 64)
When did Eton Pharmaceuticals IPO?
(ETON) raised $22 million in an initial public offering on Wednesday, November 14th 2018. The company issued 3,600,000 shares at $6.00 per share. National Securities Corporation served as the underwriter for the IPO.
Who are Eton Pharmaceuticals' major shareholders?
Eton Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Centric Wealth Management (0.16%). Company insiders that own Eton Pharmaceuticals stock include Charles J Casamento, Sean Brynjelsen and William Wilson Troutman. View Institutional Ownership Trends for Eton Pharmaceuticals.
Which major investors are buying Eton Pharmaceuticals stock?
ETON stock was purchased by a variety of institutional investors in the last quarter, including Centric Wealth Management. Company insiders that have bought Eton Pharmaceuticals stock in the last two years include Charles J Casamento, Sean Brynjelsen and William Wilson Troutman. View Insider Buying and Selling for Eton Pharmaceuticals.
How do I buy shares of Eton Pharmaceuticals?
Shares of ETON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Eton Pharmaceuticals' stock price today?
One share of ETON stock can currently be purchased for approximately $5.40.
How big of a company is Eton Pharmaceuticals?
Eton Pharmaceuticals has a market capitalization of $96.16 million. The company earns $-12,740,000.00 in net income (profit) each year or ($5.80) on an earnings per share basis. Eton Pharmaceuticals employs 15 workers across the globe.View Additional Information About Eton Pharmaceuticals.
What is Eton Pharmaceuticals' official website?
How can I contact Eton Pharmaceuticals?
Eton Pharmaceuticals' mailing address is 21925 W. FIELD PARKWAY SUITE 235, DEER PARK IL, 60010. The company can be reached via phone at 847-787-7361 or via email at [email protected]
MarketBeat Community Rating for Eton Pharmaceuticals (NASDAQ ETON)
MarketBeat's community ratings are surveys of what our community members think about Eton Pharmaceuticals and other stocks. Vote "Outperform" if you believe ETON will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ETON will underperform the S&P 500 over the long term. You may vote once every thirty days.
